HC Wainwright Equities Analysts Decrease Earnings Estimates for Celcuity Inc. (NASDAQ:CELC)

Celcuity Inc. (NASDAQ:CELC - Free Report) - HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for Celcuity in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $4.08 per share for the year, down from their prior estimate of $4.51. HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.93) per share.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.06.

A number of other equities analysts also recently issued reports on CELC. Craig Hallum reaffirmed a "buy" rating and issued a $27.00 price target (up from $25.00) on shares of Celcuity in a report on Thursday. Stifel Nicolaus reaffirmed a "buy" rating and issued a $40.00 price target on shares of Celcuity in a report on Thursday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Celcuity in a report on Thursday.

Celcuity Stock Down 5.1 %

CELC traded down $0.90 on Friday, reaching $16.76. The company's stock had a trading volume of 230,349 shares, compared to its average volume of 217,519. The stock has a 50 day moving average of $17.95 and a two-hundred day moving average of $15.62. The company has a quick ratio of 13.43, a current ratio of 13.43 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $510.34 million, a price-to-earnings ratio of -6.03 and a beta of 0.87. Celcuity has a fifty-two week low of $8.39 and a fifty-two week high of $22.19.

Institutional Investors Weigh In On Celcuity

Several large investors have recently modified their holdings of the company. Pale Fire Capital SE purchased a new stake in shares of Celcuity during the third quarter worth approximately $95,000. SG Americas Securities LLC purchased a new stake in shares of Celcuity during the fourth quarter worth approximately $139,000. Trust Point Inc. purchased a new stake in shares of Celcuity during the fourth quarter worth approximately $297,000. Commodore Capital LP raised its stake in shares of Celcuity by 3.6% during the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company's stock worth $25,566,000 after purchasing an additional 60,563 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of Celcuity during the fourth quarter worth approximately $21,583,000. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.